Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Small interfering ribonucleic acid, pharmaceutical composition and application thereof

A nucleotide and nucleotide sequence technology, applied in the field of biomedicine, can solve the problems of poor stability of siRNA, easy to be degraded by nuclease, differences between target nucleic acid species, etc., to inhibit expression, prevent and/or treat blood lipids Abnormal, total cholesterol and triglyceride reduction effects

Active Publication Date: 2018-06-29
SUZHOU RIBO LIFE SCIENCE CO LTD
View PDF2 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there are species differences in target nucleic acids, which increases the difficulty in the development of siRNA drugs targeting target nucleic acids. At the same time, the stability of siRNA is poor, and systemic drug delivery has the disadvantage of being easily degraded by nucleases.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Small interfering ribonucleic acid, pharmaceutical composition and application thereof
  • Small interfering ribonucleic acid, pharmaceutical composition and application thereof
  • Small interfering ribonucleic acid, pharmaceutical composition and application thereof

Examples

Experimental program
Comparison scheme
Effect test

preparation example 1

[0084] The sequence of siRNA is as shown in Table 2, and the positive-sense strand nucleotide sequence numbered as siAN is as shown in SEQ ID NO.4, wherein the 1-19 nucleotide sequence is as shown in SEQ ID NO. The target nucleic acid shown in NO.1 is identical; The antisense strand nucleotide sequence of this siRNA is shown in SEQ ID NO.5, wherein 1-19 nucleotide sequence is shown in SEQ ID NO.1 in table 1 target nucleic acid complementation. The sense strand nucleotide sequence numbered as siAN2 is shown in SEQ ID NO.7, wherein the 1-19 nucleotide sequence is identical to the target nucleic acid shown in SEQ ID NO.6 in the ANGPTL3 mRNA sequence; the antisense of the siRNA The chain nucleotide sequence is shown as SEQ ID NO.8, wherein the 1-19 nucleotide sequence is complementary to the target nucleic acid shown as SEQ ID NO.6 in Table 1.

[0085] As shown in Table 2, in this preparation example, an siRNA with the nucleotide sequence of the sense strand as shown in SEQ ID NO...

Embodiment 1

[0094]This example is used to detect the inhibitory rate of siRNA obtained in Preparation Example 1 on the expression level of ANGPTL3 mRNA in vitro.

[0095] The human liver cancer cell line Huh7 was inoculated in 24-well plates with DMEM complete medium containing 10% fetal bovine serum at a seeding density of 4×10 5 Cells / well, 0.5mL culture medium per well, culture overnight at 37°C.

[0096] Aspirate the cell culture medium in the 24-well plate, and add 0.5 mL Opti-MEM serum-free medium to each well. Dilute 1.5 μL of the siRNA in Preparation Example 1 and Preparation Example 2 at a concentration of 20 μM with 50 μL Opti-MEM serum-free medium; add 1 μL Lipofectamine TM 2000 (Invitrogen Company) was diluted in 50 μL Opti-MEM serum-free medium, incubated at room temperature for 5 minutes after mixing; mixed diluted siRNA and diluted Lipofectamine TM 2000, mix gently, and let stand at room temperature for 20 minutes to allow complex formation. Add the above final mixed s...

preparation example 2

[0105] The siRNA obtained after chemical modification of the siRNA sense strand and antisense strand numbered siNC is shown in Table 5, and the number is siNC-M; the four groups of siRNA obtained after chemical modification of the siRNA sense strand and antisense strand numbered siAN are shown in Table 5. 5, respectively numbered siAN-M1, siAN-M2, siAN-M3, siAN-M4. Wherein (M) represents that the pentose group in the nucleotide residue on its left side is 2'-methoxyribose group, (F) represents that the pentose group in the nucleotide residue on its left side is 2' - Fluorinated ribose; S represents that the phosphate group between the deoxyribonucleotide residues dTdT on the left and right sides is a phosphorothioate group.

[0106] table 5

[0107]

[0108]

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
diameteraaaaaaaaaa
particle diameteraaaaaaaaaa
Login to View More

Abstract

The invention relates to a small interfering ribonucleic acid, a pharmaceutical composition and application thereof. The siRNA contains a positive-sense strand and an antisense strand, wherein the positive-sense strand contains a nucleotide sequence shown as SEQ ID NO.2, and the antisense strand contains a nucleotide sequence shown as SEQ ID NO.3. Moreover, phosphate and / or ribosyl in a phosphate-sugar framework of the siRNA refers to phosphate and ribosyl with or without a modified group. The invention provides brand new efficient siRNA and the pharmaceutical composition thereof, and dyslipidemia can be effectively prevented and / or treated.

Description

technical field [0001] The present disclosure relates to the technical field of biomedicine, in particular to a small interfering nucleic acid (siRNA), a pharmaceutical composition and uses thereof. Background technique [0002] Dyslipidemia, also known as hyperlipidemia, is a systemic disease in which fat metabolism or operation is abnormal, making plasma lipids higher than normal. The clinical manifestations of hyperlipidemia mainly include two aspects: (1) xanthoma caused by lipid deposition in the dermis; (2) atherosclerosis caused by lipid deposition in the vascular endothelium, resulting in coronary heart disease and peripheral Vascular disease, etc. According to reports, approximately 35% of type 2 diabetes patients worldwide also suffer from dyslipidemia; in addition, 18 million people suffer from hypertriglyceridemia in hyperlipidemia. The prevalence of dyslipidemia among people aged 18 and over in my country is about 18.6%, and even nearly 10% of children have el...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12N15/113A61K31/713A61K47/18A61K47/10A61K47/28A61P3/06A61P9/10
CPCA61K47/10A61K47/18A61K47/28C12N15/1136C12N2310/321C12N2310/322C12N2310/315C12N2310/14A61K31/713A61P3/06A61P9/10
Inventor 张鸿雁高山
Owner SUZHOU RIBO LIFE SCIENCE CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com